Immunotoxicology Laboratory, Food, Drug & Chemical Toxicology Group and Nanomaterial Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, Uttar Pradesh, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India; Developmental Toxicology Laboratory, Systems Toxicology & Health Risk Assessment Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, Uttar Pradesh, India.
J Biol Chem. 2022 Jan;298(1):101521. doi: 10.1016/j.jbc.2021.101521. Epub 2021 Dec 22.
CD200R1 is an inhibitory surface receptor expressed in microglia and blood macrophages. Microglial CD200R1 is known to control neuroinflammation by keeping the microglia in resting state, and therefore, tight regulation of its expression is important. CCAAT/enhancer-binding protein β (CEBPβ) is the known regulator of CD200R1 transcription. In the present study, our specific intention was to find a possible posttranscriptional regulatory mechanism of CD200R1 expression. Here we investigated a novel regulatory mechanism of CD200R1 expression following exposure to an environmental stressor, arsenic, combining in silico analysis, in vitro, and in vivo experiments, as well as validation in human samples. The in silico analysis and in vitro studies with primary neonatal microglia and BV2 microglia revealed that arsenic demethylates the promoter of a microRNA, miR-129-5p, thereby increasing its expression, which subsequently represses CD200R1 by binding to its 3'-untranslated region and shuttling the CD200R1 mRNA to the cytoplasmic-processing body in mouse microglia. The role of miR-129-5p was further validated in BALB/c mouse by stereotaxically injecting anti-miR-129. We found that anti-miR-129 reversed the expression of CD200R1, as well as levels of inflammatory molecules IL-6 and TNF-α. Experiments with a CD200R1 siRNA-induced loss-of-function mouse model confirmed an miR-129-5p→CD200R1→IL-6/TNF-α signaling axis. These main findings were replicated in a human cell line and validated in human samples. Taken together, our study revealed miR-129-5p as a novel posttranscriptional regulator of CD200R1 expression with potential implications in neuroinflammation and related complications.
CD200R1 是一种表达于小胶质细胞和血液巨噬细胞的抑制性表面受体。已知小胶质细胞的 CD200R1 通过使其处于静止状态来控制神经炎症,因此,其表达的严密调控非常重要。CCAAT/增强子结合蛋白 β(CEBPβ)是 CD200R1 转录的已知调节剂。在本研究中,我们的特定意图是寻找 CD200R1 表达的可能转录后调节机制。在这里,我们通过结合计算机分析、体外和体内实验以及人类样本的验证,研究了 CD200R1 表达在暴露于环境应激源砷后的新型调节机制。计算机分析和原代新生小胶质细胞和 BV2 小胶质细胞的体外研究表明,砷使 microRNA,miR-129-5p 的启动子去甲基化,从而增加其表达,进而通过结合其 3'-非翻译区并将 CD200R1mRNA 转运到细胞质处理体中来抑制 CD200R1 的表达。在 BALB/c 小鼠中通过立体定向注射抗 miR-129 进一步验证了 miR-129-5p 的作用。我们发现抗 miR-129 逆转了 CD200R1 的表达以及炎症分子 IL-6 和 TNF-α的水平。使用 CD200R1 siRNA 诱导的功能丧失小鼠模型进行的实验证实了 miR-129-5p→CD200R1→IL-6/TNF-α 信号轴。这些主要发现已在人类细胞系中得到复制,并在人类样本中得到验证。总之,我们的研究揭示了 miR-129-5p 是 CD200R1 表达的新型转录后调节因子,其在神经炎症及其相关并发症中具有潜在的意义。